Domrachev Bogdan, Singh Sitanshu, Li Dandan, Rudloff Udo
Rare Tumor Initiative, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Thoracic & GI Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
J Cancer Treatment Diagn. 2021 Apr 30;5(1):30-35. doi: 10.29245/2578-2967/2021/1.1194.
Cancer stem cells (CSCs) are subpopulations of tumor cells that possess abilities for self-renewal, differentiation, and tumor initiation. These rare but therapy-recalcitrant cells are assumed to repopulate tumors following administration of systemic chemotherapy driving therapy failure, tumor recurrence, and disease progression. In early clinical trials, anti-CSC therapies have found limited success to-date possibly due to the inherent heterogeneity and plasticity of CSCs and the incomplete characterization of essential CSC targets. Here, we review the role of 3-phosphoinositide dependent protein kinase-1 (PDPK1) as an emerging CSC target. While most previous studies have relied on CSC models which are based on lineage and tissue-specific marker profiles to define the relationships between putative target and CSC traits, this review discusses PDPK1 and its role in CSC biology with an emphasis on CSC systems which are based on proposed function like label-retaining cancer cells (LRCCs).
癌症干细胞（CSCs）是肿瘤细胞的亚群，具有自我更新、分化和启动肿瘤的能力。这些罕见但对治疗具有抗性的细胞被认为在全身化疗后会重新填充肿瘤，从而导致治疗失败、肿瘤复发和疾病进展。在早期临床试验中，抗CSC疗法迄今取得的成功有限，这可能是由于CSCs固有的异质性和可塑性以及关键CSC靶点的表征不完整。在此，我们综述了3-磷酸肌醇依赖性蛋白激酶-1（PDPK1）作为新兴CSC靶点的作用。虽然大多数先前的研究依赖于基于谱系和组织特异性标记谱的CSC模型来定义假定靶点与CSC特征之间的关系，但本综述讨论了PDPK1及其在CSC生物学中的作用，重点是基于如标记保留癌细胞（LRCCs）等拟议功能的CSC系统。
